• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌患者淋巴细胞中阿非科林诱导的脆性位点的表达。

Expression of aphidicolin-induced fragile sites in lymphocytes of patients with breast cancer.

作者信息

Ardisia C, Venti G, Colozza M A, Breschi C, Porfirio B, Davis S, Tonato M, Donti E

机构信息

Istituto di Clinica Medica I, Università di Perugia, Italy.

出版信息

Cancer Genet Cytogenet. 1993 Jun;67(2):113-6. doi: 10.1016/0165-4608(93)90162-f.

DOI:10.1016/0165-4608(93)90162-f
PMID:8330266
Abstract

The expression of fragile sites induced by aphidicolin (APC) was evaluated on metaphase chromosomes obtained from the peripheral blood lymphocytes of 26 women with breast cancer and 15 sex- and age-matched normal controls. Both the proportion of damaged cells (P < 0.001) and the mean number of gaps and breaks per cell (0.02 < P < 0.05) were significantly higher in the patient group. There were no differences in either the age-related fragile site levels or the expression of single fragile sites between patients and controls. Our findings indicate an increased genetic instability in women with breast carcinoma.

摘要

对26名乳腺癌女性患者及15名年龄和性别匹配的正常对照者外周血淋巴细胞中期染色体上由阿非科林(APC)诱导的脆性位点表达进行了评估。患者组中受损细胞比例(P < 0.001)以及每个细胞的间隙和断裂平均数(0.02 < P < 0.05)均显著更高。患者与对照者在年龄相关脆性位点水平或单个脆性位点的表达方面均无差异。我们的研究结果表明乳腺癌女性患者的遗传不稳定性增加。

相似文献

1
Expression of aphidicolin-induced fragile sites in lymphocytes of patients with breast cancer.乳腺癌患者淋巴细胞中阿非科林诱导的脆性位点的表达。
Cancer Genet Cytogenet. 1993 Jun;67(2):113-6. doi: 10.1016/0165-4608(93)90162-f.
2
The expression of common fragile sites in peripheral blood lymphocytes of breast and colorectal cancer patients with aphidicolin.阿非科林处理下乳腺癌和结直肠癌患者外周血淋巴细胞中常见脆性位点的表达
Tohoku J Exp Med. 1999 Oct;189(2):107-16. doi: 10.1620/tjem.189.107.
3
Common fragile site expression and genetic predisposition to breast cancer.常见脆性位点表达与乳腺癌的遗传易感性。
Teratog Carcinog Mutagen. 1998;18(6):279-91. doi: 10.1002/(sici)1520-6866(1998)18:6<279::aid-tcm2>3.3.co;2-l.
4
Expression of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer, ovarian cancer, and non-small-cell lung cancer patients.阿非科林诱导的脆性位点在乳腺癌、卵巢癌和非小细胞肺癌患者中的表达及其与遗传易感性的关系。
Teratog Carcinog Mutagen. 2003;Suppl 1:35-45. doi: 10.1002/tcm.10068.
5
The expression of fragile sites in lymphocytes of patients with rectum cancer and their first-degree relatives.直肠癌患者及其一级亲属淋巴细胞中脆性位点的表达
Cancer Lett. 2000 May 1;152(2):201-9. doi: 10.1016/s0304-3835(00)00334-7.
6
The expression of aphidicolin-induced fragile sites in familial breast cancer patients.阿非科林诱导的脆性位点在家族性乳腺癌患者中的表达。
Cancer Genet Cytogenet. 1993 Jun;67(2):108-12. doi: 10.1016/0165-4608(93)90161-e.
7
Folate-sensitive and aphidicolin-inducible fragile sites are expressed in the genome of the domestic cat.对叶酸敏感且对阿非迪霉素诱导的脆性位点在家猫基因组中表达。
Cancer Genet Cytogenet. 1993 Feb;65(2):130-4. doi: 10.1016/0165-4608(93)90221-7.
8
Spontaneous unusual expression of frequency of chromosome aberrations and common fragile in human lymphocytes of colorectal cancer patients induced by Aphidicolin.阿非科林诱导的结直肠癌患者人类淋巴细胞中染色体畸变频率和常见脆性位点的自发异常表达。
J Exp Ther Oncol. 2007;6(2):175-9.
9
The expression frequency of common fragile sites and genetic predisposition to colon cancer.常见脆性位点的表达频率与结肠癌的遗传易感性。
Cancer Genet Cytogenet. 2000 Jun;119(2):139-45. doi: 10.1016/s0165-4608(99)00228-9.
10
Expression of folate sensitive and aphidicolin induced chromosomal fragile sites in familial neuroblastoma.家族性神经母细胞瘤中叶酸敏感性和阿非科林诱导的染色体脆性位点的表达
J Exp Clin Cancer Res. 2002 Sep;21(3):383-8.

引用本文的文献

1
The ubiquitous 'cancer mutational signature' 5 occurs specifically in cancers with deleted alleles.普遍存在的“癌症突变特征”5 特别出现在等位基因缺失的癌症中。
Oncotarget. 2017 Nov 6;8(60):102199-102211. doi: 10.18632/oncotarget.22321. eCollection 2017 Nov 24.